Cheaper Stroke Treatment for Third World Countries? Veronika Slonková Presented Research on Thrombolytic Enzymes in Toronto
For a successful treatment of a stroke, it is necessary to dissolve the blood clot as quickly as possible, thus restoring blood flow and, consequently, the supply of oxygen. However, without side effects. And it is precisely such medications that are being developed in the Stroke Brno cluster. One of the promising enzymes, patriotically named “brnoteplase” by scientists, had its effects presented by researcher Veronika Slonková at the 15th World Stroke Congress.
“Stroke is fast, our research is faster” is the claim of the Stroke Brno research cluster led by Professor Robert Mikulík. Stroke Brno brings together researchers and doctors from several institutions who collaborate on stroke research.
For the past five years, Veronika Slonková has been dedicated to researching and testing thrombolytic enzymes improved through protein engineering at Stroke Brno. She is studying General Medicine in the P-Pool program, which includes an extended scientific preparation. She works in the Loschmidt Laboratories under the guidance of Professor Jiří Damborský.
As a representative of the research, she traveled to Toronto, Canada, at the end of October for the 15th World Stroke Congress. She presented the results of her research on two posters. “At Stroke Brno, we focus on improving medications for stroke. Specifically, we examine thrombolytics, which are enzymes that dissolve blood clots or thrombi. Through protein engineering methods, we aim to increase the speed, selectivity, and safety of these enzymes,” explains Veronika.
Veronika Slonková during the presentation.
